National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Pharmacoeconomic evaluation and resource implications of Zytiga ® (abiraterone acetate) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have received prior docetaxel-based chemotherapy.

Rapid Review

Commenced Completed Outcome
21/10/2011 02/11/2011 Full Pharmacoeconomic Evaluation Recommended.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
12/12/2011 22/05/12  Reimbursement not recommended at the submitted price.

The NCPE believe that, at the submitted price, Abiraterone Acetate (Zytiga®) is not cost-effective for the treatment of  patients with metastatic castration-resistant prostate cancer (mCRPC) who have received prior docetaxel-based chemotherapy.

Abiraterone (Zytiga®) Summary

May 2014

The HSE has approved reimbursement following confidential price negotiations.